Journal: Journal of Thoracic Disease

Article Title: Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer

doi: 10.21037/jtd.2017.12.120

Figure Lengend Snippet: Selected ongoing combination/novel immunotherapy clinical trials with targets beyond PD-1 and CTLA-4

Article Snippet: A phase I trial of indoximod (NLG-8189, a tryptophan analog IDO inhibitor developed by NewLink Genetics), as a single agent in advanced solid malignancies, demonstrated favorable toxicity and pharmacodynamic profiles, with early response data showing some patients having SD lasting >6 months ( 58 ).

Techniques: Clinical Proteomics, Vaccines, Adjuvant, Recombinant

Journal: Therapeutic Advances in Respiratory Disease

Article Title: New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1

doi: 10.1177/1753466618794133

Figure Lengend Snippet: Selected immune checkpoint inhibitors in clinical trials.

Article Snippet: , Indoximod (NLG0401) (IDOi) , NewLink Genetics Corp , Indoximod combination with docetaxel, tergenpumatucel-L , NSCLC, at least one prior platinum-doublet chemotherapy , NCT02460367 , Phase I/II Unknown.

Techniques: Recombinant

Journal: Angewandte Chemie (International Ed. in English)

Article Title: Small Molecules Drive Big Improvements in Immuno‐Oncology Therapies

doi: 10.1002/anie.201707816

Figure Lengend Snippet: The IDO inhibitors epacadostat ( 21 ), EOS‐200271 ( 22 ), navoximod ( 23 a ) and indoximod ( 23 b ), and BMS‐986205 ( 24 ).

Article Snippet: NewLink Genetics is also investigating indoximod ( 23 b ), which is a direct inhibitor of neither IDO nor TDO at relevant pharmaceutical concentrations.

Techniques:

Journal: Neuro-Oncology

Article Title: Vaccination strategies for neuro-oncology

doi: 10.1093/neuonc/nov159

Figure Lengend Snippet: Open studies from CT.Gov 20150528

Article Snippet: 02052648 , A Phase I/II Study of the Combination of Indoximod and Temozolomide for Adult Patients With Temozolomide-Refractory Primary Malignant Brain Tumors , NewLink Genetics Corporation , In this study, investigators will conduct a phase I/II trial in recurrent (temozolomide resistant) glioma patients. The overall goal of this study is to provide a foundation for future studies with indoximod tested in newly diagnosed glioblastoma patients with radiation and temozolomide, or in combination with vaccine therapies , Indoleamine 2, 3-dioxygenase (IDO) inhibitor – Indoximod is given in combination with TMZ or bevacizumab, or with TMZ and stereotactic radiation..

Techniques: In Situ, Control, Derivative Assay, Produced, Immunopeptidomics, Expressing, Clinical Proteomics, Transplantation Assay, Vaccines, Injection, Cream, Virus, Biomarker Discovery, Recombinant, Modification

Journal: Oncotarget

Article Title: A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer

doi: 10.18632/oncotarget.24118

Figure Lengend Snippet: Square symbols represent patients enrolled at a once-daily indoximod dose level and circles represent patients enrolled at a twice-daily dose level. Blue shapes represent nonresponders and red shapes represent responders to subsequent chemotherapy. Black shapes represent patients who did not get therapy post vaccine or whose response is unknown.

Article Snippet: Indoximod (50 mg and 200 mg hard gelatin capsules) was supplied by the National Cancer Institute’s Pharmacy Branch and NewLink Genetics.

Techniques: